GRAL

GRAIL, Inc. (NASDAQ:GRAL) is a biotechnology company founded in 2015 and headquartered in Menlo Park, California. The company was spun off from genomics giant Illumina, Inc. and began trading publicly in June 2024 following regulatory pressure from European authorities. GRAIL specializes in developing multi-cancer early detection (MCED) technology, with its flagship product being the Galleri blood test that can screen for over 50 types of cancer in asymptomatic individuals. The company represents a pioneering effort in liquid biopsy technology, aiming to revolutionize cancer screening by detecting circulating tumor DNA in blood samples before traditional imaging or symptoms appear.